Vertex’ ‘next gen’ gets TGA tick

By Megan Brodie 3 years ago | In Companies, Products, Regulatory
  • 3 years ago

26 March 2021 Vertex’ next-generation cystic fibrosis (CF) treatment TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) has been…

This is subscriber-only content. Please login to continue reading.

Recent News

Top Reads